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NationwidesurveillanceofinvasivepneumococcaldiseasehasbeenconductedinGermanysince1992.From1992to2008,atotalof
12,137 isolates from invasive pneumococcal disease were collected. Data on serotypes were available for 9,394 invasive isolates. The
leading serotypes were serotypes 14 (16.5%), 3 (8.0%), 7F (7.6%), 1 (7.3%), and 23F (6.0%). Variations in serotype distribution
over the years are particularly extensive, especially concerning serotype 14 (min 7.4%, max 33.5%) with the highest percentages
among the isolates serotyped from around 1997 to 2006. Serotypes 1 and 7F increased over the last decade. No increase was
observed concerning serotype 19A. Higher pneumococcal conjugate vaccine coverages were observed among children (7v, 57.3%;
10v, 72.8%; 13v, 83.5%) than among adults (7v, 39.9%; 10v, 55.5%; 13v, 73.5%). The temporal variations in serotype distribution
have to be kept in mind when interpreting vaccine coverages reported in epidemiological studies.
1.Introduction
Streptococcus pneumoniae is one of the most important
pathogens in bacterial pneumonia, sepsis, and meningitis
worldwide [1]. Signiﬁcant temporal [2–4]a n dr e g i o n a l[ 5–
7] variations among pneumococcal serotypes have been
described. While the “epidemic” serogroups (serogroups 1-
3 and 5) decreased considerably in the United States during
the last century, the serogroups included in the seven-valent
pneumococcal conjugate vaccine (PCV7) increased clearly
[2]. A similar trend has been described in Spain, where
the prevalence of PCV7 serotypes increased signiﬁcantly
(except serotype 4) since the start of the study in the early
1980s but then decreased considerably in the 2000s for all
PCV7 serotypes except serotype 23F. Among the “epidemic”
serotypes,asigniﬁcantdecreaseofserotypes1and5hasbeen
observedinthe1980sfollowedbyasigniﬁcantincreaseinthe
late 1990s, while serotype 3 decreased continuously during
theobservational period. Furthermore,serotypes 6A, 7F, and
19A increased signiﬁcantly since the late 1990s [4].
The widespread use of antibiotics and the increasing
application of pneumococcal conjugate vaccines (a general
recommendationofpneumococcalconjugatevaccinationfor
children <2 years in Germany was issued at the end of July
2006) will have an impact on future changes in serotype
distribution.
The NRCS has conducted surveillance for invasive pneu-
mococcal disease in Germany since 1992 [8]. Between 1992
and 1996 surveillance was based on a limited number of
laboratories in Germany on a voluntary basis [9]. In 1996,
nationwide population-based surveillance of IPD in children
was started [10]. This surveillance system was extended to
adults in one federal state (North-Rhine Westphalia) in 2001
[11] and successively broadened to nationwide surveillance
until 2009.
The aim of this study was to evaluate the serotype dis-
tribution of S. pneumoniae among the isolates with invasive
pneumococcal disease (IPD) that were sent to the German
National Reference Center for Streptococci (NRCS) between
1992 and 2008, analyze temporal trends, and calculate the2 International Journal of Microbiology
Table 1
(a) Serotype distribution of IPD in Germany (1992–2008, n = 9,394) in all age groups.
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
14 8.8 12.6 7.4 8.5 13.5 16.5 17.5 29.8 33.5 25.2 21.3 22.8 23.0 18.8 19.3 13.3 8.9 16.5 1,549
3 7.1 2.9 3.7 6.0 9.4 4.2 2.7 4.3 2.8 4.0 6.6 6.7 4.9 7.5 6.4 10.5 11.7 8.0 755
7F 6.7 2.9 4.9 4.3 5.2 7.5 2.7 2.1 4.3 3.7 5.8 7.3 9.0 6.4 8.0 8.7 10.4 7.6 718
1 7.5 5.8 1.2 4.3 3.1 9.4 5.8 5.5 6.7 6.4 4.3 5.3 6.9 6.9 7.9 8.5 8.8 7.3 690
23F 8.3 9.7 6.2 8.5 9.4 6.1 8.5 8.9 6.3 7.7 8.5 5.1 4.9 6.9 6.8 4.9 4.3 6.0 559
4 7.5 11.7 4.9 5.1 2.1 5.2 7.2 3.4 3.9 3.5 4.3 7.5 4.9 6.0 6.2 5.6 4.6 5.4 507
6B 3.3 7.8 7.4 6.8 6.3 8.0 5.8 6.8 3.1 7.7 6.8 5.7 5.2 7.1 4.8 3.7 2.5 4.8 449
19F 6.7 1.9 9.9 6.8 3.1 5.2 4.9 7.7 7.1 6.9 5.2 3.8 5.4 5.4 4.5 4.5 3.4 4.8 447
9V 4.2 1.0 8.6 6.0 8.3 2.8 3.1 6.4 5.5 2.2 3.3 5.3 5.6 4.8 5.1 5.1 3.6 4.5 425
6A 6.7 5.8 4.9 8.5 3.1 5.2 5.4 2.6 4.3 3.5 3.5 4.6 3.9 2.8 3.1 4.9 4.6 4.3 401
18C 4.6 4.9 6.2 1.7 1.0 6.6 6.7 3.8 7.5 4.5 4.3 2.9 3.6 3.4 3.6 2.3 3.0 3.5 326
19A 0.8 2.9 1.2 1.7 5.2 2.4 5.8 3.4 4.3 3.0 1.4 1.6 2.6 2.9 4.3 4.0 4.2 3.4 320
22F 1.3 2.9 3.7 0.0 2.1 0.5 0.9 0.0 0.0 0.7 1.0 1.0 1.5 3.0 3.0 2.9 3.0 2.2 208
8 2.1 1.9 0.0 0.9 2.1 0.5 0.9 0.0 0.4 1.5 2.3 2.1 2.1 2.5 2.2 2.5 3.0 2.2 208
10A 1.7 1.0 3.7 2.6 2.1 1.4 1.3 0.9 1.6 1.7 2.5 0.6 2.2 1.5 1.9 1.9 2.2 1.8 172
9N 2.1 1.0 1.2 3.4 1.0 1.4 0.9 1.3 1.6 1.2 1.7 1.3 1.3 1.4 1.6 2.0 2.6 1.8 172
11A 2.5 1.9 1.2 1.7 4.2 1.4 0.4 0.9 0.0 0.2 0.6 1.8 1.5 1.3 1.1 1.7 2.5 1.6 149
12F 2.5 1.9 2.5 1.7 6.3 1.4 1.3 1.3 0.0 2.2 1.0 1.8 0.7 0.4 0.4 1.0 1.7 1.3 118
24F 2.1 1.0 1.2 0.9 1.0 0.5 1.8 1.3 0.8 2.0 0.6 1.3 1.5 0.7 1.2 0.9 1.8 1.2 116
23A 0.8 1.0 1.2 0.0 0.0 0.9 1.3 0.0 0.8 0.5 0.8 0.8 0.2 0.4 0.8 1.0 1.7 0.9 88
15B 0.8 1.9 0.0 0.0 1.0 0.0 0.9 0.9 1.2 0.0 0.6 0.3 0.9 1.1 0.9 1.0 1.2 0.9 83
35F 0.8 0.0 1.2 0.9 0.0 0.5 0.4 0.9 0.8 0.5 0.0 0.3 0.0 0.4 0.5 0.7 1.8 0.8 74
33F 1.3 1.0 1.2 0.9 0.0 0.9 1.8 0.9 0.0 0.5 0.6 1.0 0.9 0.7 0.2 0.6 0.9 0.7 68
38 0.4 0.0 2.5 0.0 0.0 0.9 0.4 0.0 0.4 0.5 0.6 0.6 0.7 0.2 0.3 0.4 1.4 0.6 61
5 1.3 0.0 2.5 0.9 2.1 1.4 0.9 0.9 0.0 0.2 0.8 0.2 0.4 0.4 0.5 0.4 0.7 0.6 55
15C 1.7 0.0 0.0 1.7 0.0 3.8 0.0 0.0 0.4 0.0 0.4 0.6 0.4 0.6 0.9 0.5 0.3 0.6 53
15A 0.0 0.0 0.0 1.7 0.0 0.0 1.8 1.7 0.0 0.7 1.2 0.8 0.7 0.6 0.5 0.1 0.4 0.5 48
9A 0.4 1.0 1.2 0.9 2.1 0.9 0.9 0.0 0.8 3.5 2.1 0.6 0.0 0.4 0.0 0.2 0.0 0.5 47
20 0.8 1.9 2.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.6 0.6 0.8 0.3 0.6 0.4 0.5 43
NT 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.4 0.0 0.2 0.2 0.0 0.7 0.4 0.3 0.7 0.5 0.4 40
17F 0.0 1.9 0.0 0.9 0.0 0.0 0.9 0.0 0.0 0.0 1.2 0.3 0.7 0.8 0.3 0.4 0.2 0.4 39
16F 0.0 0.0 0.0 1.7 1.0 0.5 0.0 0.4 0.0 1.0 0.6 0.5 0.4 0.2 0.4 0.1 0.4 0.4 34
33A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.8 0.5 0.2 0.3 30
31 0.8 0.0 1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.5 0.4 0.5 0.0 0.1 0.3 0.1 0.5 0.3 26
18A 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.4 0.6 0.2 0.2 0.1 0.3 0.2 0.2 22
34 0.8 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.4 0.3 0.2 0.2 0.2 0.3 0.2 0.2 22
rough 0.0 1.0 1.2 0.9 1.0 0.0 0.0 0.0 0.4 0.5 1.0 1.3 0.0 0.0 0.0 0.0 0.0 0.2 20
23B 0.0 1.0 0.0 0.0 0.0 0.5 0.4 0.0 0.0 0.5 0.0 0.2 0.4 0.1 0.1 0.1 0.2 0.2 17
9L 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.7 0.8 0.3 0.2 0.0 0.2 0.2 0.0 0.2 17
13 0.0 2.9 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.2 0.6 0.0 0.2 0.0 0.0 0.1 0.1 0.2 15
18F 0.4 1.9 0.0 0.9 0.0 0.5 0.0 0.9 0.0 0.0 0.2 0.2 0.0 0.1 0.0 0.3 0.0 0.2 15
2 0.4 1.0 1.2 0.9 0.0 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.1 13
12A 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.2 0.0 0.2 0.0 0.3 0.2 0.0 0.1 12
28A 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.4 0.0 0.4 0.2 0.0 0.1 0.1 0.2 0.0 0.1 12International Journal of Microbiology 3
(a) Continued.
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
35B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.2 0.2 0.1 11
10B 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.2 0.1 0.1 10
Others 2.9 1.9 2.5 7.7 3.1 0.5 4.9 1.7 1.2 1.5 0.6 1.6 0.6 1.3 0.3 1.7 0.9 1.4 130
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 9,394
Not
sero-
typed
52.5 77.8 76.0 67.0 67.7 40.8 40.5 43.9 38.2 39.4 29.9 21.5 19.1 1.5 0.0 0.1 0.0 22.6 2,743
NT: nontypeable; n: number of isolates tested.
Others includes the serotypes (number of isolates): 15F (9), 18B (9), 12B (8), 7C (8), 33B (7), 10F (6), 11B (6), 11F (6), 35A (6), 19C (5), 29 (5), 37 (5), 21
(4), 24A (4), 28F (4), 35C (4), 19B (3), 22A (3), 36 (3), 45 (3), 7A (3), 24B (2), 25F (2), 39 (2), 48 (2), 6 (2), 7B (2), 12 (1), 17A (1), 18 (1), 19 (1), 23 (1), 35
(1), 9 (1).
(b) Serotype distribution of IPD in Germany (1992–2008, n = 2,948) in children (<16 years).
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
14 12.8 6.9 14.3 5.9 16.7 15.2 18.0 26.9 31.5 25.5 26.7 27.0 30.6 26.3 25.4 13.9 5.6 22.5 664
1 2.1 3.4 3.6 0.0 0.0 9.5 5.6 6.6 8.0 8.4 5.4 4.5 6.0 7.6 10.5 12.5 12.9 7.9 234
6B 6.4 13.8 0.0 11.8 8.3 8.9 6.2 7.7 3.5 7.5 8.9 7.8 7.2 10.8 6.6 7.0 4.3 7.3 216
19F 8.5 3.4 7.1 23.5 0.0 6.3 6.8 8.8 8.0 9.6 5.4 5.7 6.8 7.3 8.0 8.4 4.7 7.2 213
23F 10.6 3.4 7.1 11.8 16.7 7.0 7.5 8.2 5.5 7.9 10.5 6.1 4.9 6.6 8.7 6.2 2.6 6.9 204
7F 2.1 3.4 0.0 5.9 0.0 7.6 3.7 2.2 5.5 4.6 5.8 8.6 7.9 6.0 7.7 9.9 13.8 6.9 204
18C 8.5 10.3 17.9 0.0 0.0 8.9 8.7 4.9 8.0 6.3 5.8 5.7 3.8 5.4 6.6 5.1 5.6 6.2 182
6A 14.9 20.7 3.6 5.9 0.0 5.1 5.6 2.7 4.5 3.8 4.7 4.9 3.8 3.5 1.4 4.8 5.6 4.4 130
9V 4.3 3.4 14.3 11.8 8.3 2.5 2.5 7.1 4.0 2.1 2.3 4.1 4.2 5.1 3.1 3.3 1.3 3.7 108
4 6.4 10.3 7.1 11.8 8.3 5.1 7.5 3.8 4.0 2.1 3.5 3.7 3.0 2.8 3.1 2.2 0.4 3.5 102
3 4.3 3.4 3.6 5.9 0.0 3.8 1.9 3.8 3.0 2.9 3.1 3.3 1.5 1.9 2.4 5.9 5.6 3.3 96
19A 0.0 3.4 0.0 0.0 8.3 1.9 6.2 2.2 3.5 2.5 1.6 2.0 3.0 2.5 3.8 4.0 4.7 3.1 90
10A 2.1 0.0 0.0 0.0 0.0 0.6 0.0 1.1 1.5 2.1 1.6 0.4 2.3 1.9 2.8 2.2 3.4 1.7 51
24F 4.3 3.4 0.0 0.0 0.0 0.0 2.5 1.6 1.0 2.1 0.8 2.5 1.9 0.6 1.4 1.1 2.2 1.5 44
15B 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.1 1.0 0.0 0.4 0.4 0.8 1.3 0.7 2.2 2.2 0.9 26
15C 2.1 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 0.4 0.8 0.4 1.3 1.4 0.4 2.2 0.9 26
9N 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.1 1.5 0.8 0.4 1.6 1.5 0.3 1.0 0.4 1.7 0.9 26
38 2.1 0.0 3.6 0.0 0.0 0.6 0.6 0.0 0.5 0.4 0.8 0.4 0.8 0.3 0.0 0.7 3.9 0.8 23
15A 0.0 0.0 0.0 0.0 0.0 0.0 1.2 1.6 0.0 0.4 1.2 1.6 0.8 0.6 1.0 0.0 0.4 0.7 21
22F 0.0 0.0 7.1 0.0 0.0 0.6 0.6 0.0 0.0 0.8 1.2 1.2 0.8 0.6 0.3 0.4 1.3 0.7 21
9A 0.0 0.0 0.0 0.0 0.0 1.3 0.6 0.0 1.0 3.8 1.9 0.8 0.0 0.0 0.0 0.0 0.0 0.7 21
5 0.0 0.0 3.6 0.0 8.3 1.9 1.2 1.1 0.0 0.0 0.8 0.0 0.8 0.9 0.3 0.0 0.9 0.6 19
8 0.0 0.0 0.0 0.0 0.0 0.6 1.2 0.0 0.5 0.4 1.2 0.4 0.8 0.9 0.7 0.4 0.4 0.6 18
33F 0.0 0.0 0.0 0.0 0.0 1.3 1.9 0.5 0.0 0.4 1.2 0.8 0.4 0.0 0.0 0.4 1.3 0.6 17
12F 2.1 0.0 3.6 0.0 0.0 0.0 0.6 1.1 0.0 1.7 0.0 0.0 0.8 0.0 0.0 0.4 1.7 0.5 16
11A 0.0 0.0 0.0 0.0 8.3 1.9 0.0 0.5 0.0 0.0 0.4 1.2 0.0 0.0 0.3 1.1 0.9 0.5 15
23A 2.1 0.0 0.0 0.0 0.0 0.6 1.2 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.7 0.4 1.7 0.5 14
18A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.8 0.8 0.4 0.0 0.0 0.4 0.9 0.3 10
35F 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.5 1.0 0.0 0.0 0.0 0.0 0.3 0.3 0.4 1.3 0.3 10
NT 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 1.5 0.3 0.0 0.7 0.9 0.3 10
33A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.3 0.7 0.4 0.4 0.3 9
rough 0.0 3.4 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.8 0.8 1.2 0.0 0.0 0.0 0.0 0.0 0.3 9
17F 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.8 0.3 0.0 0.4 0.9 0.3 8
16F 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.8 0.4 0.0 0.0 0.3 0.0 0.0 0.9 0.2 7
18B 0.0 0.0 0.0 0.0 8.3 0.0 1.2 0.5 0.5 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.2 74 International Journal of Microbiology
(b) Continued.
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
23B 0.0 3.4 0.0 0.0 0.0 0.6 0.6 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0 0.4 0.2 6
34 2.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.7 0.0 0.2 6
18F 0.0 0.0 0.0 0.0 0.0 0.6 0.0 1.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.2 5
20 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.4 0.4 0.3 0.0 0.4 0.0 0.2 5
9L 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.4 0.0 0.0 0.3 0.0 0.0 0.2 5
Others 2.1 3.4 3.6 5.9 8.3 2.5 2.5 1.6 1.5 0.8 0.8 0.4 1.5 1.6 0.3 3.3 3.0 1.7 50
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 2,948
Not
sero-
typed
7.8 17.1 3.4 34.6 61.3 7.1 2.4 3.2 3.8 0.0 0.4 0.8 0.0 0.0 0.0 0.0 0.0 2.4 72
NT: nontypeable; n: number of isolates tested.
Others includes the serotypes (number of isolates): 28A (4), 11B (3), 12A (3), 12B (3), 13 (3), 33B (3), 35B (3), 15F (2), 19C (2), 21 (2), 24A (2), 28F (2),
29 (2), 35A (2), 37 (2), 7A (2), 10F (1), 19B (1), 2 (1), 31 (1), 35 (1), 35C (1), 36 (1), 39 (1), 6 (1), 7C (1).
(c) Serotype distribution of IPD in Germany (1992–2008, n = 6,446) in adults (≥16 years).
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
14 7.8 14.9 3.8 9.0 13.1 20.4 16.1 39.6 40.7 24.8 15.1 20.1 15.6 14.8 16.6 13.2 9.4 13.7 885
3 7.8 2.7 3.8 6.0 10.7 5.6 4.8 5.7 1.9 5.5 10.7 8.9 8.1 10.5 8.3 11.2 12.5 10.2 659
7F 7.8 2.7 7.5 4.0 6.0 7.4 0.0 1.9 0.0 2.4 5.8 6.5 10.0 6.6 8.1 8.5 9.9 8.0 514
1 8.8 6.8 0.0 5.0 3.6 9.3 6.5 1.9 1.9 3.6 3.1 5.7 7.8 6.5 6.7 7.8 8.3 7.1 456
4 7.8 12.2 3.8 4.0 1.2 5.6 6.5 1.9 3.7 5.5 5.3 9.9 6.7 7.7 7.6 6.1 5.2 6.3 405
23F 7.8 12.2 5.7 8.0 8.3 3.7 11.3 11.3 9.3 7.3 6.2 4.4 4.8 7.0 5.9 4.7 4.5 5.5 355
9V 4.1 0.0 5.7 5.0 8.3 3.7 4.8 3.8 11.1 2.4 4.4 6.0 7.0 4.6 6.1 5.4 3.9 4.9 317
6A 4.7 0.0 5.7 9.0 3.6 5.6 4.8 1.9 3.7 3.0 2.2 4.4 4.1 2.4 3.8 4.9 4.5 4.2 271
19F 6.2 1.4 11.3 4.0 3.6 1.9 0.0 3.8 3.7 3.0 4.9 2.6 4.1 4.4 2.9 3.8 3.3 3.6 234
6B 2.6 5.4 11.3 6.0 6.0 5.6 4.8 3.8 1.9 7.9 4.4 4.4 3.3 5.1 4.0 3.2 2.3 3.6 233
19A 1.0 2.7 1.9 2.0 4.8 3.7 4.8 7.5 7.4 3.6 1.3 1.3 2.2 3.1 4.5 4.0 4.1 3.6 230
8 2.6 2.7 0.0 1.0 2.4 0.0 0.0 0.0 0.0 3.0 3.6 3.1 3.3 3.4 2.9 2.8 3.4 2.9 190
22F 1.6 4.1 1.9 0.0 2.4 0.0 1.6 0.0 0.0 0.6 0.9 0.8 2.2 4.3 4.1 3.3 3.3 2.9 187
9N 2.6 1.4 1.9 4.0 1.2 5.6 1.6 1.9 1.9 1.8 3.1 1.0 1.1 2.0 1.9 2.3 2.7 2.3 146
18C 3.6 2.7 0.0 2.0 1.2 0.0 1.6 0.0 5.6 1.8 2.7 1.0 3.3 2.4 2.2 1.8 2.7 2.2 144
11A 3.1 2.7 1.9 2.0 3.6 0.0 1.6 1.9 0.0 0.6 0.9 2.1 3.0 2.0 1.4 1.8 2.7 2.1 134
10A 1.6 1.4 5.7 3.0 2.4 3.7 4.8 0.0 1.9 1.2 3.6 0.8 2.2 1.4 1.4 1.8 2.0 1.9 121
12F 2.6 2.7 1.9 2.0 7.1 5.6 3.2 1.9 0.0 3.0 2.2 2.9 0.7 0.7 0.6 1.1 1.7 1.6 102
23A 0.5 1.4 1.9 0.0 0.0 1.9 1.6 0.0 1.9 1.2 1.3 1.0 0.4 0.7 0.8 1.1 1.7 1.1 74
24F 1.6 0.0 1.9 1.0 1.2 1.9 0.0 0.0 0.0 1.8 0.4 0.5 1.1 0.7 1.1 0.8 1.7 1.1 72
35F 1.0 0.0 1.9 1.0 0.0 1.9 0.0 1.9 0.0 1.2 0.0 0.5 0.0 0.5 0.6 0.8 1.9 1.0 64
15B 1.0 2.7 0.0 0.0 1.2 0.0 1.6 0.0 1.9 0.0 0.9 0.3 1.1 1.0 1.0 0.8 1.1 0.9 57
33F 1.6 1.4 1.9 1.0 0.0 0.0 1.6 1.9 0.0 0.6 0.0 1.0 1.5 1.0 0.3 0.6 0.9 0.8 51
20 1.0 2.7 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.7 1.0 0.5 0.6 0.4 0.6 38
38 0.0 0.0 1.9 0.0 0.0 1.9 0.0 0.0 0.0 0.6 0.4 0.8 0.7 0.2 0.5 0.3 1.1 0.6 38
5 1.6 0.0 1.9 1.0 1.2 0.0 0.0 0.0 0.0 0.6 0.9 0.3 0.0 0.2 0.6 0.5 0.7 0.6 36
17F 0.0 2.7 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.5 0.7 1.0 0.5 0.4 0.2 0.5 31
NT 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.6 0.4 0.0 0.0 0.5 0.5 0.7 0.5 0.5 30
15A 0.0 0.0 0.0 2.0 0.0 0.0 3.2 1.9 0.0 1.2 1.3 0.3 0.7 0.5 0.3 0.1 0.4 0.4 27
15C 1.6 0.0 0.0 2.0 0.0 1.9 0.0 0.0 1.9 0.0 0.4 0.5 0.4 0.2 0.6 0.5 0.1 0.4 27
16F 0.0 0.0 0.0 2.0 1.2 0.0 0.0 1.9 0.0 1.2 0.9 0.8 0.7 0.2 0.6 0.1 0.4 0.4 27
9A 0.5 1.4 1.9 1.0 2.4 0.0 1.6 0.0 0.0 3.0 2.2 0.5 0.0 0.7 0.0 0.2 0.0 0.4 26
31 1.0 0.0 1.9 1.0 0.0 0.0 0.0 0.0 0.0 1.2 0.9 0.8 0.0 0.2 0.5 0.1 0.5 0.4 25International Journal of Microbiology 5
(c) Continued.
Sero-
type
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
Total
(%)
Total
(n)
33A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.8 0.5 0.2 0.3 21
34 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.5 0.0 0.2 0.3 0.2 0.2 0.2 16
13 0.0 4.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 1.3 0.0 0.4 0.0 0.0 0.1 0.2 0.2 12
18A 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.3 0.2 0.2 0.1 0.2 12
2 0.5 0.0 1.9 1.0 0.0 1.9 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.2 12
9L 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 1.2 0.9 0.3 0.4 0.0 0.2 0.2 0.0 0.2 12
23B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.4 0.2 0.2 0.1 0.2 0.2 11
rough 0.0 0.0 1.9 1.0 1.2 0.0 0.0 0.0 0.0 0.0 1.3 1.3 0.0 0.0 0.0 0.0 0.0 0.2 11
10B 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.4 0.3 0.0 0.2 0.2 0.2 10
18F 0.5 2.7 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.2 0.0 0.2 10
12A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.5 0.2 0.1 0.1 9
28A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.3 0.0 0.0 0.2 0.2 0.0 0.1 8
35B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 8
15F 0.5 0.0 0.0 1.0 0.0 0.0 0.0 1.9 0.0 0.0 0.4 0.3 0.4 0.0 0.0 0.1 0.0 0.1 7
7C 0.5 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 0.2 0.1 7
11F 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 6
10F 0.5 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.1 0.1 0.1 5
12B 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 5
Others 1.0 2.7 1.9 6.0 1.2 0.0 8.1 0.0 0.0 1.8 0.4 1.6 0.0 0.9 0.3 0.8 0.6 0.9 58
Total 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 6,446
Not
sero-
typed
57.5 82.8 82.8 69.6 68.4 71.3 70.5 77.1 73.4 61.4 47.7 30.7 31.8 2.3 0.0 0.1 0.0 29.3 2,671
NT: nontypeable; n: number of isolates tested.
Others includes the serotypes (number of isolates): 33B (4), 35A (4), 11B (3), 19C (3), 22A (3), 29 (3), 35C (3), 37 (3), 45 (3), 18B (2), 19B (2), 21 (2), 24A
(2), 24B (2), 25F (2), 28F (2), 36 (2), 48 (2), 7B (2), 12 (1), 17A (1), 18 (1), 19 (1), 23 (1), 39 (1), 6 (1), 7A (1), 9 (1).
Table 2: Distribution of isolates serotyped among pneumococcal isolates sent to the NRCS in Germany (1992–2008).
Isolates
serotyped
1992
(%)
1993
(%)
1994
(%)
1995
(%)
1996
(%)
1997
(%)
1998
(%)
1999
(%)
2000
(%)
2001
(%)
2002
(%)
2003
(%)
2004
(%)
2005
(%)
2006
(%)
2007
(%)
2008
(%)
children
serotyped
(%) 92,2 82,9 96,6 65,4 38,7 92,9 97,6 96,8 96,2 100,0 99,6 99,2 100,0 100,0 100,0 100,0 100,0
serotyped
(n) 47 29 28 17 12 158 161 182 200 239 258 244 265 316 287 273 232
total 51 35 29 26 31 170 165 188 208 239 259 246 265 316 287 273 232
adults
serotyped
(%) 42,5 17,2 17,2 30,4 31,6 28,7 29,5 22,9 26,6 38,6 52,3 69,3 68,2 97,7 100,0 99,9 100,0
serotyped
(n) 193 74 53 100 84 54 62 53 54 165 225 384 270 588 628 1654 1805
Total 454 429 309 329 266 188 210 231 203 428 430 554 396 602 628 1655 1805
overall
serotyped
(%) 47,5 22,2 24,0 33,0 32,3 59,2 59,5 56,1 61,8 60,6 70,1 78,5 80,9 98,5 100,0 99,9 100,0
serotyped
(n) 240 103 81 117 96 212 223 235 254 404 483 628 535 904 915 1927 2037
total 505 464 338 355 297 358 375 419 411 667 689 800 661 918 915 1928 20376 International Journal of Microbiology
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Figure 1: (a) Distribution of the epidemic serotypes 1, 2, 3, and 5 in percent (1992–2008, n = 9,394) in all age groups. (b) Distribution of
the epidemic serotypes 1–3 and 5 among children in percent (1992–2008, n = 2,948). (c) Distribution of the epidemic serotypes 1–3 and 5
among adults in percent (1992–2008, n = 6,446).
vaccine coverages for the 7-valent, 10-valent, and 13-valent
pneumococcal conjugate vaccines.
2.MaterialsandMethods
2.1. Study Design. In this study data about invasive disease
caused by Streptococcus pneumoniae in children (<16 years)
and adults (≥16 years) in Germany were included using the
data sources described above. Cases from January 1, 1992 to
December 31, 2008 were included in this study. A case of
IPD was deﬁned by the isolation of S. pneumoniae from a
normally sterile site.
2.2. Microbiological Investigations. Isolates were identiﬁed
using standard procedures including bile solubility and
optochin sensitivity. As a control strain, Streptococcus pneu-
moniae ATCC 49619 was used. Pneumococcal isolates were
serotypedbytheNeufeld’sQuellungreactionusingtype-and
factor-speciﬁc antisera (Statens Serum Institut, Copenhagen,
Denmark). Among isolates of adults, high levels of resistance
were a main trigger for initiation of serotyping during the
early years of this study. Since cross-reactive serotypes were
not included in the calculation, coverage information strictly
refers to the serotypes included in the vaccines. Serogroup 6
isolates were not tested with respect to serotype 6C.
3. Results
Atotalof12,137isolatesfrominvasivepneumococcaldisease
were collected between January 1, 1992 and December 31,
2008. The total numbers of cases for each year varied
between 297 and 2,037 cases (median: 505 cases). Data
on serotypes were available for 9,394 isolates (77.4% of
all invasive isolates; 31.4% children, 68.6% adults; 54.9%
male, 43.7% female, 1.4% no information on gender). The
serotype distribution of the years 1992–2008 is shown in
Table 1(a). The leading serotypes were serotypes 14 (16.5%),
3 (8.0%), 7F (7.6%), 1 (7.3%), and 23F (6.0 %). Concerning
the epidemic serotypes 1–3 and 5, a slight increase was
noticed during the last years, reaching levels around 20%
among children and adults in 2008 (Figures 1(a)–1(c)).
Variations in serotype distribution over the years are partly
extensive, especially concerning serotype 14 (min 7.4%, max
33.5%) (Figure 2(a)). Diﬀerences in serotype distribution
amongchildrenandadultsareshowninTables1(b)and1(c).
The amount of serotyped isolates among all pneumococcal
isolates sent to the NRCS in Germany is shown in Table 2.
Over the years the percentage of isolates serotyped increased
continuously and in the last four years of the study almost all
isolates were serotyped.
Serotype 14 is considerably more frequent among chil-
dren (22.5%) than among adults (13.7%). Overall, an
increase of serotype 14 can be noticed from around 1997
to 2006 (Figure 2(a)). A high percentage of serotype 14
isolates remain in existence for a longer time among children
(1999–2006, Figure 2(b)) than among adults (1999–2001,
Figure 2(c)). Serotype 1 and serotype 7F have been clearly
increasing over the last approximately 10 years, both among
childrenandamongadults.Whileforchildrenthepercentage8 International Journal of Microbiology
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Figure 2: (a) Distribution of the 7-valent pneumococcal conjugate vaccine serotypes and the 7-valent vaccine coverage in percent (1992–
2008, n = 9,394). (b) Distribution of the 7-valent pneumococcal conjugate vaccine serotypes and the 7-valent vaccine coverage among
children in percent (1992–2008, n = 2,948). (c) Distribution of the 7-valent pneumococcal conjugate vaccine serotypes and the 7-valent
vaccine coverage among adults in percent (1992–2008, n = 6,446).
of serotypes 1 and 7F reach the highest values during this
study in 2008, among adults they are high, but still within
the range already noted before (Figures 3(a)-3(c)). Serotype
3 is far more common among adults (10.2%) than among
children (3.3%) (Tables 1(b)-1(c)). The increase observed
during the last years seems to be slightly higher among
adults than among children (Figures 4(a)–4(c)). Concerning
serotype 19A no clear change in frequency can be observed
during the period under study (Figures 4(a)–4(c)).
Variations in serotype distribution also aﬀect theoretical
vaccine coverages. The overall serotype coverage for the 7-
valent conjugate vaccine was 45.4% during 1992–2008. For
the 10-valent vaccine and the 13-valent vaccine the overall
coverages were 60.9% and 76.6%, respectively. Generally,
higher coverages were observed among children (7v, 57.3%;
10v, 72.8%; 13v, 83.5%) than among adults (7v, 39.9%; 10v,
55.5%; 13v, 73.5%). Among children, the coverage of the 7-
valent vaccine decreased from 64.2% in 2005 to 24.6% in
2008 (Figure 2(b)), while for adults the coverage declined
to a lesser extent (2005, 45.9%; 2008, 31.2%) (Figure 2(c)).
Temporal changes of the additional 10-valent and 13-valent
pneumococcal vaccine serotypes and the corresponding
vaccine coverages are shown in Figures 3(a)–3(c) (10v) and
Figures 4(a)–4(c) (13v). Since the general recommendation
of pneumococcal conjugate vaccination for children <2y e a r s
in Germany at the end of July 2006 a percentage increase
among the new (10v) or upcoming (13v) vaccine serotypes
was noticed especially for serotypes 1 and 7F in children
(Figure 3(b)) and for serotype 3 in adults (Figure 4(c)).
In comparison, coverages of the 23-valent polysaccharide
vaccine are very similar among children (min, 69.0%; max,
92.3%) and adults (min, 71.0%; max, 92.6%) from 1992 to
2008 (Figure 5).
4. Discussion
In this paper we present the results of 17 years of surveillance
concerning serotypes of invasive pneumococcal disease in
Germany.
In the present study serotype 14 was the most prevalent
serotype among children, followed in frequency by the
serotypes 1, 6B, 19F, 23F, and 7F, respectively. These data are
similar to those published for German children previously
[12, 13] and in line with data from England [14], Belgium
[15], and Denmark [16]. Among adults, the most frequent
serotypes were 14, 3, 7F, 1, 4, and 23F (sorted in descending
order). These results are similar to a previous study from the
NRCS among adults in North-Rhine Westphalia, Germany,
between 2003 and 2006 [17], and are generally in line with
results reported from other countries [6, 15, 18–20]; how-
ever, they deviate in part from older German data [12, 21].
The variation of serotype 14 over the years is extensive
in our study with an increased prevalence from about 1997
to 2006, reaching maximum values in 2000. Although the
rate of serotyped isolates among adults was low from 1999 to
2001 (1999, 22.9%; 2000, 26.6%; 2001, 38.6%), the increase
seems plausible. First, the increase among adults is paralleled
by an increase among children, where nearly all isolates have10 International Journal of Microbiology
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Figure 3: (a) Distribution of the additional 10v-pneumococcal conjugate vaccine serotypes 1, 5, and 7F and the 10-valent vaccine coverage
in percent (1992–2008, n = 9,394). (b) Distribution of the additional 10v-pneumococcal conjugate vaccine serotypes 1, 5, and 7F and
the 10-valent vaccine coverage among children in percent (1992–2008, n = 2,948). (c) Distribution of the additional 10v-pneumococcal
conjugate vaccine serotypes 1, 5, and 7F and the 10-valent vaccine coverage among adults in percent (1992–2008, n = 6,446).
been serotyped. Second, the rate of isolates serotyped among
adults is within the range serotyped in the years before 1999,
where a similar increase of serotype 14 was not observed.
Furthermore, similar data have been shown in a report from
Spain [4]. Also, a small rise in frequency of serotype 14 has
been reported from Denmark in 1995–1999 [16], and data
from England demonstrated a rise in incidence in 2000 and
2001 [14]. The rise of serotypes 1 and 7F for nearly one
decade is similar to results from Spain [4].
Concerning serotype 19A, the highest prevalences were
observed in 1996 (8.3%) and 1998 (6.2%) among children,
andin1999(7.5%)and2000(7.4%)amongadults.Although
there seems to be a slight upward movement during the years
2002 to 2008, the prevalences still are below the maximum
values reported. The increase of serotype 19A reported from
other countries [4, 22, 23] has not been found in Germany
so far.
Although changes in the incidence of diﬀerent serotypes
have been reported, the reasons for this are not fully
understood [14]. Potential reasons discussed are changes
in socioeconomic conditions, antibiotic use and resistance
levels, immunocompromised status of populations, precise
age distributions of the populations studied and increased
life expectancy, and blood-culturing rates [2, 6, 24]. Since
the general recommendation of pneumococcal conjugate
vaccination for children <2 years in Germany at end of July
2006 a reduction in the percentage of IPD caused by the
7-valent vaccine serotypes was observed [25]. This eﬀect
is more apparent among children, but also present among
the adult population. Similar results have been reported
from other countries [3, 4, 26–29]. Logically, the percentage
decrease in vaccine serotypes is paralleled by a percentage
increase in the amount of IPD caused by nonvaccine
serotypes, which was most prominent for serotypes 1 and 7F
in children and serotype 3 in adults in this study. Serotype
coverage for the 7-valent conjugate vaccine in Germany was
45.4% from 1992 to 2008. Calculated coverages for the 10-
valent vaccine and 13-valent vaccine are 60.9% and 76.6%,
respectively. These data are comparable to those previously
reported [5, 14, 30, 31]. Coverages of all three vaccine
formulationsinourstudyareapproximately15%(7v,17.4%;
10v, 17.3%; and 13v, 10.0%) higher among children than
among adults. Diﬀerences in age distribution among study
populations are known to have a major impact on vaccine
coverage of the current and proposed vaccines for diﬀerent
age groups and, furthermore, comparable data have been
published [14].
Nevertheless, some factors and limitations must be
regarded when interpreting the results of this study. First of
all, the isolates were sent by the participating laboratories
on a voluntary basis, as participation in surveillance is
not mandatory in Germany. Furthermore, the systematic
sampling of invasive isolates from adults (1992) and children
(1997) was taken up at diﬀerent points of time, and the
included population-based studies in three German federal
states started in 2001 (North Rhine-Wesphalia) and 200612 International Journal of Microbiology
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Figure 4: (a) Distribution of the additional 13v-pneumococcal conjugate vaccine serotypes 3, 6A, and 19A and the 13-valent vaccine
coverage in percent (1992–2008, n = 9,394). (b) Distribution of the additional 13v-pneumococcal conjugate vaccine serotypes 3, 6A,
and 19A and the 13-valent vaccine coverage among children in percent (1992–2008, n = 2,948). (c) Distribution of the additional
13v-pneumococcal conjugate vaccine serotypes 3, 6A, and 19A and the 13-valent vaccine coverage among adults in percent (1992–2008,
n = 6,446).
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Figure 5: Coverage of the 23v-pneumococcal polysaccharide vaccine for children (n = 2,948), adults (n = 6,446), and overall (n = 9,394).14 International Journal of Microbiology
(Bavaria and Saxony). Among isolates of adults, high levels
of resistance were a main trigger for initiation of serotyping
during the early years of this study. Therefore, the isolates
may not be fully representative of all IPD in Germany over
the last two decades.
Moreover, the structure of the surveillance project has
been continousely improved over the 15 years and, in par-
ticular, after the general recommendation of pneumococcal
conjugate vaccine for children <2 years in Germany at the
end of July 2006 an increased disease awareness by both
clinical micobiologists and pediatricians was observed [32].
Ongoing nationwide surveillance is necessary to observe
furtherdevelopmentsofpneumococcalserotypedistribution
in Germany.
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